Garbage In, Garbage Out: The Case for More Accurate Process Modeling in Manufacturing Economics - A case study in capturing indirect costs and benefits. - BioPharm International

ADVERTISEMENT

Garbage In, Garbage Out: The Case for More Accurate Process Modeling in Manufacturing Economics
A case study in capturing indirect costs and benefits.


BioPharm International
Volume 22, Issue 8

CONCLUSION

In conclusion, biopharmaceutical manufacturing's current proliferation of capacity and the trend toward an increasing number of small-volume products creates unique challenges in manufacturing economics studies. The high indirect costs of biopharmaceutical manufacturing means that any plant downtime for retrofitting raise the bar for performance improvement efforts to overcome. Typically, improvements with significant benefit to the organization focus on creating additional capacity (or additional effective capacity, such as reduced changeover times). In such analyses, however, producing accurate process models is of vital importance in establishing correct metrics around the economic benefits of any scenarios considered.

Rick Johnston is co-director at the Center for Biopharmaceutical Operations, University of California, Berkeley, and David Zhang is principal at Bioproduction Group, Inc. Berkeley, CA, 650.823.7533,

REFERENCES

1. The University of California at Berkeley. Center for Biopharmaceutical Operations; 2009. Available frome: http://cbo.berkeley.edu/.

2. Numbers indicative only.

3. Bioproduction Group. Indicative times only, not from any specific single biopharmaceutical manufacturer. Comparative durations for times retained, X and Y scales normalized. Processing step includes inline testing. Rejected batches removed.

4. Yang A. Genentech Simulation System. CBO Workshop; 21 May 2008. Available from: http://cbo.berkeley.edu/.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here